CD8A and neoplasm: Another interesting approach is the use of SCH58261, a new generation of A2A adenosine receptor ICI blocker that inhibits the immunosuppressive adenosinergic pathway in the tumor microenvironment, activating NK cells and CD8+ T cells, and inhibiting the proliferation of Tregs.